Effect of Yangxinshi Tablet on Exercise Tolerance in Patients With Chronic Coronary Syndrome（MET STUDY）
Efficacy and Safety of Yangxinshi Tablet in Improving Exercise Tolerance in Patients With Chronic Coronary Syndrome(Qi Deficiency and Blood Stasis Syndrome):A Randomized, Double-blind,Placebo-parallel-controlled,Multicenter Clinical Study
Sponsor: Dongzhimen Hospital, Beijing
A PHASE4 clinical study on Chronic Coronary Syndrome, this trial is ongoing. The trial is conducted by Dongzhimen Hospital, Beijing and has accumulated 6 data snapshots since 2023. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
6 versions recorded-
Feb 2026 — Present [monthly]
Unknown PHASE4
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2026 [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Nov 2023 — Jan 2024 [monthly]
Not Yet Recruiting PHASE4
▶ Show 1 earlier version
-
Sep 2023 — Nov 2023 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Dongzhimen Hospital, Beijing
For direct contact, visit the study record on ClinicalTrials.gov .